Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and ...

Pfizer sees mixed Q1 signals as growth in key drugs offsets COVID declines. Can pipeline strength and M&A bets support long-term upside?

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...

Pfizer Inc PFE shares are dipping on Tuesday. The company announced a series of settlement agreements that extend the effective U.S. patent life of Vyndamax, its treatment for transthyretin‑mediated ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

The healthcare giant has been investing heavily in its future growth.

View Pfizer Inc. PFE stock quote prices, financial information, real-time forecasts, and company news from CNN.

On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on ...

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement ...

Investors who seek out dividend stocks pay close attention to a company's dividend yield, and high-yield players -- as long ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer’s recent positive data for atirmociclib, tilrekimig, Padcev, and the Lyme disease vaccine candidate highlight pipeline ...